0000950170-24-024913.txt : 20240304
0000950170-24-024913.hdr.sgml : 20240304
20240304171823
ACCESSION NUMBER: 0000950170-24-024913
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240301
FILED AS OF DATE: 20240304
DATE AS OF CHANGE: 20240304
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Keson-Brookes Maiken
CENTRAL INDEX KEY: 0001693805
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41837
FILM NUMBER: 24715620
MAIL ADDRESS:
STREET 1: 35 OAK HILL ROAD
CITY: FAYVILLE
STATE: MA
ZIP: 01745
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Mural Oncology plc
CENTRAL INDEX KEY: 0001971543
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: L2
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10 EARLSFORT TERRACE
CITY: DUBLIN 2
STATE: L2
ZIP: D02 T380
BUSINESS PHONE: 353 1 905 8020
MAIL ADDRESS:
STREET 1: 10 EARLSFORT TERRACE
CITY: DUBLIN 2
STATE: L2
ZIP: D02 T380
FORMER COMPANY:
FORMER CONFORMED NAME: Mural Oncology Ltd
DATE OF NAME CHANGE: 20230403
FORMER COMPANY:
FORMER CONFORMED NAME: Pistachiovale Ltd
DATE OF NAME CHANGE: 20230329
4
1
ownership.xml
4
X0508
4
2024-03-01
0001971543
Mural Oncology plc
MURA
0001693805
Keson-Brookes Maiken
C/O MURAL ONCOLOGY PLC
10 EARLSFORT TERRACE
DUBLIN 2
L2
D02 T380
IRELAND
false
true
false
false
See Remarks
false
Ordinary Shares
2024-03-01
4
A
false
16800
0.00
A
46007
D
Stock Option (right to buy)
5.39
2024-03-01
4
A
false
31200
0.00
A
2034-02-28
Ordinary Shares
31200
31200
D
Consists of ordinary shares issuable under 16,800 restricted stock units ("RSUs"). Each RSU represents the right to receive one ordinary share upon vesting. The RSUs are scheduled to vest with respect to 25% of the underlying ordinary shares on each of the first four anniversaries of March 1, 2024, subject to the reporting person's continued service with the Issuer.
This option was granted on March 1, 2024. The option is scheduled to vest with respect to 25% of the underlying ordinary shares on March 1, 2025 and the remaining 75% of the underlying ordinary shares shall vest in 12 equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer.
Chief Legal Officer and Secretary
/s/ Maiken Keson-Brookes
2024-03-04